Bio tech company updates — 5/2/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korea's biotech sector remains in the spotlight as fresh data from KHIDI reveals the nation's bio-health industry revenue reached 143.55 trillion won in 2024, and Ecolab Life Sciences has opened a new Bioprocessing Applications Laboratory (BPAL) in Korea. Meanwhile, AstraZeneca Korea has outlined its AI-bio partnership strategy at BIO KOREA 2026, reinforcing the country's growing reputation as a global biotech hub.
Key Findings
-
Korea's bio-health industry revenue reached 143.55 trillion won (~$104B USD) in 2024, representing a 7.6% year-on-year increase, with R&D spending surging 14.3% to 8.54 trillion won, according to data from KHIDI.
-
Ecolab Life Sciences opened a new Bioprocessing Applications Laboratory (BPAL) in Korea, designed to help bioprocessing manufacturers address process challenges earlier in development and reduce overall development risk.
-
AstraZeneca Korea participated in BIO KOREA 2026, the nation's largest bio-health convention, where it outlined its collaborations and strategy to support Korea's AI-bio ecosystem in alignment with government initiatives, speaking at the Open Innovation session.
Details
Korea Bio-Health Industry Posts Record Revenue
Korea's bio-health sector has posted robust growth, with the Korea Health Industry Development Institute (KHIDI) reporting 2024 full-year revenue of 143.55 trillion won — up 7.6% from the prior year. The standout figure is R&D investment, which climbed 14.3% to 8.54 trillion won, signaling that Korean companies are not only generating revenue but aggressively reinvesting in their innovation pipelines.
Ecolab Opens Bioprocessing Lab in Korea
Ecolab Life Sciences has inaugurated a new Bioprocessing Applications Laboratory (BPAL) in Korea, adding to the country's growing infrastructure for advanced biomanufacturing. According to Genetic Engineering & Biotechnology News, the facility was specifically created to enable manufacturers to tackle process challenges at earlier development stages and cut development risk — a critical need as Korea's biosimilar and biologic production capacity continues to expand.
AstraZeneca Korea Champions AI-Bio Ecosystem at BIO KOREA 2026
AstraZeneca Korea used the platform of BIO KOREA 2026 to publicly articulate its vision for Korea's AI-driven biotech future. Speaking at the Open Innovation session, the company described its collaborative strategy to support the country's AI-bio ecosystem in line with government-led biotech initiatives. The company's participation underscores the growing role of multinational pharma players in shaping Korea's domestic innovation landscape.
Sources
K-Pharma-Bio One Team Launches to Unify Global Expansion Support - Seoul Economic Daily
Eli Lilly Visits Korea to Unveil Biotech Incubation Strategy With Samsung Biologics - Seoul Economic
en.sedaily.com
koreabiomed.com
genengnews.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
